Medplus Health Services Ltd Q1 FY27 Earnings Analysis

- MedPlus aims to continue a balanced growth approach, focusing on both branded and private label products rather than aggressive private label expansion alone. - The company expects to add approximately 800 new stores in FY27, including both company-owned and franchisee stores, indicating continued network expansion. - Same-store sales growth (SSSG) target remains at an annualized rate of 9% to 10% over the next year. - Private label growth guidance remains intact, aiming for a 20-30 basis points increase every quarter in private label share. - Emphasis on increasing private label non-pharma product assortment to add topline and bottom-line benefits. - Expansion into Tier 2 and Tier 3 towns continues, with more focus on physical stores in these markets complemented by online convenience. - The company does not currently provide specific revenue or volume growth guidance but anticipates maintaining or improving current performance levels.

- The company expects to maintain or improve gross margins, driven by increasing private label share. - EBITDA margins are targeted to be stabilized around current levels (5.7%-5.8%) in the near term, with potential for gradual growth. - Same-store sales growth (SSSG) guidance is 9%-10% annualized, supporting steady revenue growth. - Expansion through franchisee model to accelerate store additions without diluting margins significantly. - Growth in private label non-pharma products is anticipated to contribute positively to both top-line and bottom-line. - Free cash flow generation continues robustly, enabling reinvestment for growth rather than dividends currently. - Management maintains a cautious but optimistic outlook on steadily growing operating profits/EPS aligned with network expansion and margin improvement.

- MedPlus plans to upgrade or modernize at least 600+ existing stores within the current year to accommodate more products, optimizing space and introducing smarter shelving/rack systems including pharma and non-pharma segmentation. (Page 16) - Expansion through franchisee model is ongoing, with approximately 310 franchisee stores added recently, supporting faster network growth alongside company-owned store expansion. (Page 5) - The company expects to continue store additions (around 800 stores next year), split between owned and franchisee stores, with more detailed splits to be shared in the future. (Page 5) - New warehouses may be added as the company expands into new states or further penetrates existing newer states like Madhya Pradesh and Chhattisgarh, though current warehouse capacity suffices for existing stores. (Page 7) - MedPlus is mindful about capital allocation focused on areas where it can add more value and achieve optimum shareholder returns, including private label manufacturing and supply chain enhancements. (Page 11) No specific quantitative capex guidance provided; focus remains on strategic store modernizations and network expansion.

- MedPlus Health Services Limited currently operates as a zero-debt company with no external loans on its books. - Interest expenses reported relate only to lease accounting, not actual loans. - The company has not indicated any plans for new fundraising through debt or equity in the near term. - Focus is on organic growth via store expansion (both company-owned and franchisee) and private label development. - Management prioritizes capital allocation to maximize returns, with no explicit announcements on fresh capital raises. - Free cash flow generation is strong, but the company has not yet committed to dividend payouts or external fundraising. - Overall, no current or immediate future plans for debt or equity fundraising were disclosed during the call.

The provided document (pages 1-19 of MedPlus Health Services Limited May 21, 2026) does not contain any information related to current or expected order book or pending orders. The transcript mainly focuses on: - Inventory holding periods and returns (<1% returns) - Lease accounting and zero external debt - Warehouse inventory levels (30-33 days sustainable level) - Sales and margins including private label growth - Store formats and franchisee model details - Online vs physical store growth dynamics - Financial performance highlights (store margins, SSSG, EBITDA margins) - Free cash flow and dividend considerations No specific details on order book or pending orders are disclosed.